Nature Reviews Gastroenterology & Hepatology

Papers
(The H4-Index of Nature Reviews Gastroenterology & Hepatology is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Regulating protease homeostasis in irritable bowel syndrome730
Hybrid EASL Congress 2023528
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity497
Zolbetuximab treatment in metastatic gastric cancer495
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection484
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis425
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology412
Digestive Disease Week 2022374
Mapping neuroimmune interactions in the gut362
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa332
2023 FDA approvals in gastroenterology and hepatology326
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed323
Western lifestyle, metaflammation and the cell of origin of colon cancer319
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection311
Large language models for clinical decision support in gastroenterology and hepatology299
Black–White disparities across the colorectal cancer care continuum in the USA280
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis245
Leveraging diet to engineer the gut microbiome226
Nomenclature of HBV core protein-targeting antivirals224
Artificial intelligence and automation in endoscopy and surgery215
Hepatic IRF3 in glucose intolerance209
Oral microbiome therapy efficacious for recurrent C. difficile infection195
Wound healing in the colon190
GWAS reveals variants for alcohol-related hepatocellular carcinoma187
A crucial Fusobacterium nucleatum clade in colorectal cancer185
The global burden of coeliac disease: opportunities and challenges183
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges180
Inflammatory bowel disease in pregnancy and breastfeeding175
Decoding therapy resistance in liver tumours: a giant leap171
New understanding of hepatobiliary MRI169
Lessons from incretin-based therapy in MASH and obesity165
Metastatic pancreatic cancer and the liver162
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract160
Bacteriophages and their potential for treatment of gastrointestinal diseases159
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation154
Integrated systems approach to identify environmental factors in intestinal inflammation149
Hepatocyte-derived biomarkers in alcohol-related cirrhosis143
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases132
Metabolic diseases in the East Asian populations131
Lanifibranor and NASH resolution130
Implications of the evolving knowledge of the genetic architecture of MASLD128
Estimating dietary intake from human stool DNA123
Characterizing the genomic landscape of colorectal cancer118
HDCA ameliorates NAFLD in mice116
Probiotics for preterms: sharing complex decision-making115
The path to successful hepatitis C elimination in Spain113
Liver, ageing and disease113
SSRIs and depression: role of gut–brain communication112
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook110
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management109
Human intestinal B cells in inflammatory diseases106
Medical therapy of paediatric inflammatory bowel disease106
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment102
Current and future colorectal cancer screening strategies101
Preventing the progression of cirrhosis to decompensation and death100
Author Correction: Hepatic immune regulation and sex disparities99
ECCO’2499
NAFLD prevalence in older patients with T2DM96
Phase III results for first-line treatment for metastatic colorectal cancer95
Microbiota and colorectal cancer — controlling for confounders challenges associations94
Gut microbiome and autism spectrum disorder93
Enteric nervous system transfers stress to the gut91
GLP1R agonists in NAFLD: a promising therapy on the horizon88
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’87
Transforming the landscape of liver cancer detection and care86
Artificial intelligence in liver cancer — new tools for research and patient management85
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance85
Neutrophils as potential therapeutic targets in hepatocellular carcinoma81
The future of pathology in gastroenterology and hepatology80
Foundations of gastrointestinal-based drug delivery and future developments79
Hepatic glucose metabolism in the steatotic liver77
Hepatic inflammatory responses in liver fibrosis76
SMART cancer risk prediction74
Immunoregulatory role of enteric glia74
Liver dialysis in ACLF74
0.072923898696899